Citigroup
ONCO icon

Citigroup’s Onconetix ONCO Stock Holding History

Citigroup’s Portfolio ONCO Stock Details ONCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-172
Closed -$2.56K – 6107
2026
Q1 		$2.56K Buy
+172
New +$8.96K ﹤0.01% 5394
2022
Q2 		– Hold
0
– -$135K – 6535
2022
Q1 		– Hold
0
– – – 4279

Other funds holding ONCO

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup's ONCO Position: Q2 2026 in Review

Citigroup sold out of Onconetix (ONCO) in Q2 2026, closing a stake of 172 shares — an estimated $2.56K sold.

Citigroup first reported a position in ONCO in Q1 2026 and held it in 1 quarter. The position peaked at $2.56K in Q1 2026. 6 funds tracked by Wall St. Rank hold ONCO as of Q2 2026.

  • Citigroup reported no remaining Onconetix position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 172 Onconetix shares in Q2 2026, an estimated $2.56K.
  • Citigroup first reported a position in Onconetix in Q1 2026 and held it in 1 quarter.
  • Citigroup's Onconetix position peaked at $2.56K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Onconetix as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.